RU95118764A - DRUG FOR TREATMENT OF PURULENT WASES ON THE BACKGROUND OF DIABETES MELLITUS - Google Patents

DRUG FOR TREATMENT OF PURULENT WASES ON THE BACKGROUND OF DIABETES MELLITUS

Info

Publication number
RU95118764A
RU95118764A RU95118764/14A RU95118764A RU95118764A RU 95118764 A RU95118764 A RU 95118764A RU 95118764/14 A RU95118764/14 A RU 95118764/14A RU 95118764 A RU95118764 A RU 95118764A RU 95118764 A RU95118764 A RU 95118764A
Authority
RU
Russia
Prior art keywords
treatment
diabetes mellitus
purulent
wases
drug
Prior art date
Application number
RU95118764/14A
Other languages
Russian (ru)
Other versions
RU2112548C1 (en
Inventor
Е.А. Строев
Д.В. Селиверстов
А.Д. Чичкун
Б.Я. Гаусман
Original Assignee
Рязанский государственный медицинский университет им.акад.И.П.Павлова
Filing date
Publication date
Application filed by Рязанский государственный медицинский университет им.акад.И.П.Павлова filed Critical Рязанский государственный медицинский университет им.акад.И.П.Павлова
Priority to RU95118764A priority Critical patent/RU2112548C1/en
Priority claimed from RU95118764A external-priority patent/RU2112548C1/en
Publication of RU95118764A publication Critical patent/RU95118764A/en
Application granted granted Critical
Publication of RU2112548C1 publication Critical patent/RU2112548C1/en

Links

Claims (1)

Препарат для лечения гнойных ран на фоне сахарного диабета, содержащий террилитин, эмульсионную основу, эмульгатор и консервант, отличающийся тем, что в качестве активного соединения содержит террилитин, в качестве эмульгатора - аубазидан и дополнительно новокаин, масло оливковое, глицерин, ланолин, масло лаванды, аэросил при следующем соотношении компонентов, мас. %:
Террилитин - 8000 - 10000 ПЕ
Новокаин - 0,25 - 0,3
Масло оливковое - 15,0 - 20,0
Глицерин - 10,0
Аубазидан - 0,7 - 1,0
Ланолин безводный - 3,0
Моноглицериды дистиллированные - 3,0
Масло лаванды - 1,0
Нипагин: нипазол - 0,2
Аэросил - 10,0
Вода дистиллированная - 170,0лA preparation for the treatment of purulent wounds against diabetes mellitus, containing terrilithin, an emulsion base, an emulsifier and a preservative, characterized in that it contains terrilithin as an active compound, aubazidan and additionally novocaine, olive oil, glycerin, lanolin, lavender oil, as an emulsifier aerosil in the following ratio of components, wt. %:
Terrilitin - 8000 - 10000 PE
Novocaine - 0.25 - 0.3
Olive oil - 15.0 - 20.0
Glycerin - 10.0
Aubazidan - 0.7 - 1.0
Anhydrous Lanolin - 3.0
Distilled monoglycerides - 3.0
Lavender Oil - 1.0
Nipagin: nipazole - 0.2
Aerosil - 10.0
Distilled water - 170.0l
RU95118764A 1995-11-03 1995-11-03 Preparation for suppurative wound treatment at diabetes mellitus background RU2112548C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU95118764A RU2112548C1 (en) 1995-11-03 1995-11-03 Preparation for suppurative wound treatment at diabetes mellitus background

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU95118764A RU2112548C1 (en) 1995-11-03 1995-11-03 Preparation for suppurative wound treatment at diabetes mellitus background

Publications (2)

Publication Number Publication Date
RU95118764A true RU95118764A (en) 1998-01-10
RU2112548C1 RU2112548C1 (en) 1998-06-10

Family

ID=20173466

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95118764A RU2112548C1 (en) 1995-11-03 1995-11-03 Preparation for suppurative wound treatment at diabetes mellitus background

Country Status (1)

Country Link
RU (1) RU2112548C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2844716B1 (en) * 2002-09-23 2008-11-21 Marcel Jacques Chicouri NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR FOOD HYGIENE OF DIABETICS

Similar Documents

Publication Publication Date Title
CA2166388A1 (en) Antifungal composition for external use retentive in stratum corneum
ATE222748T1 (en) ORAL COMPOSITION WITH IMPROVED ABSORPTION
KR950002785A (en) Parathyroid hormone and raloxyphene to increase bone mass
EP0382066A3 (en) Use of dihydroliponic acid as an analgetic, antiphlogistic and/or cytoprotective agent
DK261490D0 (en) NEW PHARMACEUTICAL COMPOUND
ATE15596T1 (en) PHARMACEUTICAL AGENT.
CA2284774A1 (en) Theobromine antitussive compositions
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
CA2148112A1 (en) New pharmaeutical dosage form for transdermal administration
CA2283255A1 (en) Use of r-nsaid's for the prevention of alzheimer's disease
FR2836336B1 (en) USE IN A COSMETIC TREATMENT OF A PHENOLIC FRACTION RICH IN DIHYDROCHALCONES
KR950016760A (en) Hemorrhoids Treatment
US4404198A (en) Phenyl Salicylate as a topical anti-inflammatory
EP1023901A4 (en) Ameliorant for hepatitis c remedial effect and application thereof
RU95118764A (en) DRUG FOR TREATMENT OF PURULENT WASES ON THE BACKGROUND OF DIABETES MELLITUS
RU2209064C2 (en) New application in medicinal purposes
KR970704442A (en) (S) -adenosyl-L-methionine (SAMe) and its physiologically compatible salts for the treatment of reperfusion injury induced by transient lesion ischemia (Use of (S) -Adenosy-L-Methionine Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)
RU98101105A (en) NEW APPLICATION FOR MEDICAL PURPOSES
KR880009656A (en) Treatment or prophylaxis of local periodontal disease
KR960003717A (en) Use of elliprodil and its enantiomers for the manufacture of a medicament useful for the prevention of peripheral neuropathy caused by anticancer agents
RU94027255A (en) Multicomponent ointment and method of its preparing
KR920019349A (en) Use of R (+)-3-amino-1-hydroxy-pyrrolidin-2-one to treat anxiety
EP0335446A3 (en) Agents for treating neoplasms
RU98103858A (en) DRUG FOR TREATING LONGLY HEALING INFECTED ULCERS AND RAS
RU98102520A (en) ANTIMICROBIAL DRUG FOR TREATMENT OF INFECTED RAS